Varda Space Industries Launches W-7 Spacecraft to Test the Effects of Microgravity on Cancer Drug Solubility

·by Henderson·Engineering
Varda Space Industries Launches W-7 Spacecraft to Test the Effects of Microgravity on Cancer Drug Solubility
Key Points
  • Varda Space Industries launches W-7 spacecraft to test cancer drug solubility.
  • The experiment will observe the solubility of crystals grown in orbit.
  • PROTACs drugs have poor solubility in bodily fluids, affecting drug conversion.
  • If successful, it could pave the way for clinical development.

California-based Varda Space Industries launched a spacecraft named W-7 on October 20 to test whether a microgravity environment can help a class of experimental cancer drugs dissolve more effectively. According to The Guardian, this launch marks the first time Varda has three spacecraft operating in orbit simultaneously, as the other two were launched together on October 1. Varda aims to make orbital processing a routine part of drug development. The experiment addresses a common issue, as Varda states that poor solubility is one of the main reasons promising drug candidates fail, as the human body cannot absorb them.

Observing Crystal Behavior in Orbit

Varda hopes to observe whether crystals grown in orbit dissolve more easily than those grown on the ground. The company states that this could ultimately lead to drugs that are easier to absorb and more effective, although this has yet to be confirmed.

The payload being tested on W-7 mixes liquid with active pharmaceutical ingredients, which, according to Varda, are the components responsible for the therapeutic effects of the drugs. This compound belongs to a class of drugs known as PROTACs, which stands for "proteolysis-targeting chimeras." These drugs do not inhibit pathogenic proteins but instead mark them for destruction by cells. Varda states that PROTACs are large, complex molecules with poor solubility in bodily fluids, making them difficult to convert into usable drugs.

According to Meganne Christian, space manufacturing mission manager at the UK Space Agency, gravity on Earth causes particles to settle and creates currents in liquids, both of which interfere with crystal growth. Varda states that in a microgravity environment, molecules can form crystals that are more soluble.

Michael Reilly, Varda's Chief Strategy Officer, stated that the company is "looking for new ways to make powerful drugs more effective." According to Space.com, Varda's first mission launched in June 2023, growing crystals of the HIV drug ritonavir, which will be brought back to Earth in February 2024. According to Varda, these crystals must return to Earth for analysis to determine if they are more soluble. The release did not provide a return date.

Potential Impact of Success

If the results obtained are significant, the company states that this could pave the way for clinical development, meaning testing in humans.

Cost is another barrier. Christian told The Guardian, "This won't be commercially viable for every application." Other companies are also pursuing similar goals. The American space company Redwire's subsidiary SpaceMD has booked a SpaceX mission in 2028 that could carry up to 32 drug research laboratories. The company states that since November 2023, its 54 PIL-BOX laboratories have flown to the International Space Station.

Cardiff-based company Space Forge aims to grow semiconductor crystals in orbit for use in electronics. The company's ForgeStar-1 satellite has operated a high-temperature furnace in space, but it has yet to bring unfinished materials back to Earth, according to The Guardian. Varda has also planned more flight missions. Reilly stated that the company plans to collaborate with United Therapeutics on a mission for lung disease treatment, expected to take place "sometime next year," while The Guardian reported that Varda plans to conduct seven more missions in 2027.

Potential of Microgravity Environments for Drug Development

The launch of Varda Space Industries' W-7 spacecraft, aimed at exploring the effects of microgravity on cancer drug solubility, showcases the potential of space technology in the medical field. Poor drug solubility is a reason for the failure of many drug candidates, and through experiments in space, Varda hopes to overcome this challenge and develop more effective drugs. This could not only change the way drugs are developed but also provide new directions for future clinical trials, thereby advancing medical technology.

H
About the author
Henderson